Literature DB >> 32467352

Pharmacological Properties of δ-Opioid Receptor-Mediated Behaviors: Agonist Efficacy and Receptor Reserve.

Isaac J Dripps1, Ruizhuo Chen1, Amanda M Shafer1, Kathryn E Livingston1, Alexander Disney1, Stephen M Husbands1, John R Traynor1, Kenner C Rice1, Emily M Jutkiewicz2.   

Abstract

δ-Opioid receptor (δ-receptor) agonists produce antihyperalgesia, antidepressant-like effects, and convulsions in animals. However, the role of agonist efficacy in generating different δ-receptor-mediated behaviors has not been thoroughly investigated. To this end, efficacy requirements for δ-receptor-mediated antihyperalgesia, antidepressant-like effects, and convulsions were evaluated by comparing the effects of the partial agonist BU48 and the full agonist SNC80 and changes in the potency of SNC80 after δ-receptor elimination. Antihyperalgesia was measured in a nitroglycerin-induced thermal hyperalgesia assay. An antidepressant-like effect was evaluated in the forced swim test. Mice were observed for convulsions after treatment with SNC80 or the δ-opioid receptor partial agonist BU48. Ligand-induced G protein activation was measured by [35S]guanosine 5'-O-[γ-thio]triphosphate binding in mouse forebrain tissue, and δ-receptor number was measured by [3H]D-Pen2,5-enkephalin saturation binding. BU48 produced antidepressant-like effects and convulsions but antagonized SNC80-induced antihyperalgesia and G protein activation. The potency of SNC80 was shifted to the right in δ-receptor heterozygous knockout mice and naltrindole-5'-isothiocyanate-treated mice, and the magnitude of potency shift differed across assays, with the largest shift occurring in the thermal hyperalgesia assay, followed by the forced swim test and then convulsion observation. Naltrindole antagonized these SNC80-induced behaviors with similar potencies, suggesting that these effects are mediated by the same type of δ-receptor. These data suggest that δ-receptor-mediated behaviors display a rank order of efficacy requirement, with antihyperalgesia having the highest requirement, followed by antidepressant-like effects and then convulsions. These findings further our understanding of the pharmacological mechanisms mediating the in vivo effects of δ-opioid receptor agonists. SIGNIFICANCE STATEMENT: δ-Opioid receptor (δ-receptor) agonists produce antihyperalgesia, antidepressant-like effects, and convulsions in animal models. This study evaluates pharmacological properties, specifically the role of agonist efficacy and receptor reserve, underlying these δ-receptor-mediated behaviors. These data suggest that δ-receptor-mediated behaviors display a rank order of efficacy requirement, with antihyperalgesia having the highest requirement, followed by antidepressant-like effects and then convulsions.
Copyright © 2020 by The Author(s).

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32467352      PMCID: PMC7372918          DOI: 10.1124/jpet.119.262717

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  34 in total

1.  Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses.

Authors:  D Filliol; S Ghozland; J Chluba; M Martin; H W Matthes; F Simonin; K Befort; C Gavériaux-Ruff; A Dierich; M LeMeur; O Valverde; R Maldonado; B L Kieffer
Journal:  Nat Genet       Date:  2000-06       Impact factor: 38.330

2.  Receptor heterodimerization leads to a switch in signaling: beta-arrestin2-mediated ERK activation by mu-delta opioid receptor heterodimers.

Authors:  Raphael Rozenfeld; Lakshmi A Devi
Journal:  FASEB J       Date:  2007-03-23       Impact factor: 5.191

3.  Behavioral effects of the delta-selective opioid agonist SNC80 and related compounds in rhesus monkeys.

Authors:  S S Negus; M B Gatch; N K Mello; X Zhang; K Rice
Journal:  J Pharmacol Exp Ther       Date:  1998-07       Impact factor: 4.030

4.  Nonpeptidic delta-opioid receptor agonists reduce immobility in the forced swim assay in rats.

Authors:  Daniel C Broom; Emily M Jutkiewicz; John E Folk; John R Traynor; Kenner C Rice; James H Woods
Journal:  Neuropsychopharmacology       Date:  2002-06       Impact factor: 7.853

Review 5.  Genetic mouse models of depression.

Authors:  Christopher Barkus
Journal:  Curr Top Behav Neurosci       Date:  2013

6.  Antihyperalgesic effects of delta opioid agonists in a rat model of chronic inflammation.

Authors:  G L Fraser; G A Gaudreau; P B Clarke; D P Ménard; M N Perkins
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

7.  Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats.

Authors:  Stephen D Mague; Andrea M Pliakas; Mark S Todtenkopf; Hilarie C Tomasiewicz; Yan Zhang; William C Stevens; Robert M Jones; Philip S Portoghese; William A Carlezon
Journal:  J Pharmacol Exp Ther       Date:  2003-04       Impact factor: 4.030

8.  The role of regulator of G protein signaling 4 in delta-opioid receptor-mediated behaviors.

Authors:  Isaac J Dripps; Qin Wang; Richard R Neubig; Kenner C Rice; John R Traynor; Emily M Jutkiewicz
Journal:  Psychopharmacology (Berl)       Date:  2016-09-13       Impact factor: 4.530

9.  Behavioral despair in mice: a primary screening test for antidepressants.

Authors:  R D Porsolt; A Bertin; M Jalfre
Journal:  Arch Int Pharmacodyn Ther       Date:  1977-10

10.  Delta-opioid agonists: differential efficacy and potency of SNC80, its 3-OH (SNC86) and 3-desoxy (SNC162) derivatives in Sprague-Dawley rats.

Authors:  Emily M Jutkiewicz; Erik B Eller; John E Folk; Kenner C Rice; John R Traynor; James H Woods
Journal:  J Pharmacol Exp Ther       Date:  2004-01-13       Impact factor: 4.030

View more
  2 in total

1.  Reply to Zhuang et al.: Potential side effects of positive allosteric modulators of the mu-opioid receptor.

Authors:  John R Traynor
Journal:  Proc Natl Acad Sci U S A       Date:  2021-07-13       Impact factor: 11.205

2.  Exploration of beta-arrestin isoform signaling pathways in delta opioid receptor agonist-induced convulsions.

Authors:  Arryn T Blaine; Yiming Miao; Jinling Yuan; Sophia Palant; Rebecca J Liu; Zhong-Yin Zhang; Richard M van Rijn
Journal:  Front Pharmacol       Date:  2022-08-11       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.